타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 148 trials |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan, sacituzumab govitecan, brentuximabvedo |
Technology Linker | linker technologies, and targets to expand the applicability of ADCs across broader NS |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration)) Daiichi Sankyo Co., Ltd.·Non-Small Cell Lung Cancer Metasta… 148 trials |
|---|---|
Overview Program | Patritumab Deruxtecan (Up-Titration) |
Overview Company | Daiichi Sankyo Co., Ltd. |
Overview Modality | ADC |
Overview Target | Non-Small Cell Lung Cancer Metastatic |
Overview Indication | Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Editorial scope · structured catalog |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | deruxtecan, sacituzumab govitecan, brentuximabvedo |
Technology Linker | linker technologies, and targets to expand the applicability of ADCs across broader NS |
MoA Mechanism | antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancer |
MoA Biomarker | biomarkers will give new insights on individual MTX metabolism and drug adherence |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교